Publications

Export 188 results:
Sort by: [ Author  (Asc)] Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
E
El-Karaksy, H., G. Anwar, S. Mansour, N. El-Koofy, R. El-Sayed, H. Helmy, H. Mina, M. Sabry, and G. Esmat. "HEPATIC IMPAIRMENT IN EGYPTIAN CHILDREN WITH TYPE I DIABETES MELLITUS." JOURNAL OF HEPATOLOGY 50}, Meeting Abstract = {611 (2009): S225. Abstract
n/a
El-Karaksy, H., S. Nomachi, and G. Esmat. "Living related liver transplantation from a heterozygote donor in Wilson's disease: follow-up after 30 months." LIVER INTERNATIONAL 26 (2006): 98. Abstract
n/a
El-Karaksy, Hanaa Mostafa, Ghada Anwar, Gamal Esmat, Samah Mansour, Magda Sabry, Heba Helmy, Ahmad El-Hennawy, and Hanan Fouad. "Prevalence of hepatic abnormalities in a cohort of Egyptian children with type 1 diabetes mellitus." PEDIATRIC DIABETES 11 (2010): 462-470. Abstract
n/a
El-Raziky, M. S., M. El-Hawary, N. El-Koofy, S Okasha, M Isa, M. Kotb, K. Salama, G. Esmat, M. El-Raziky, A. M. Abouzied, and H. El-Karaksy. "Hepatitis C virus infection in Egyptian children: single centre experience." JOURNAL OF VIRAL HEPATITIS 11 (2004): 471-476. Abstract
n/a
El-Raziky, M., W. El-Akel, M. Soliman, S. El-Kafrawy, M. Abdel-Hamid, and G. Esmat. "HCV relapse in sustained responders to interferon therapy for chronic hepatitis C genotype 4." JOURNAL OF CLINICAL VIROLOGY 36 (2006): S141. Abstract
n/a
El-Raziky, M. S., M. El-Hawary, G. Esmat, A. M. Abouzied, N. El-Koofy, N. Mohsen, S. Mansour, A. Shaheen, Abdel M. Hamid, and H. El-Karaksy. "Prevalence and risk factors of asymiptomatic hepatitis C virus infection in Egyptian children." WORLD JOURNAL OF GASTROENTEROLOGY 13 (2007): 1828-1832. Abstract
n/a
El-Raziky, M. S., WA El-Akel, M. A. Soliman, S. El-Kafrawy, M. Abdel-Hamid, and G. Esmat. "HCV RNA in peripheral blood mononuclear cells (PBMNCS) of sustained virological responders to interferon based therapies: Is it a risk for relapse?" HEPATOLOGY 42 (2005): 431A. Abstract
n/a
El-Sayed, M., M. El-Raziky, A. Elsharkawy, H. Khattab, A. H. K. Abdelmaksoud, M. K. Ashour, and G. Esmat. "COMPARISON BETWEEN DIFFUSION-WEIGHTED MRI, FIBROSCAN AND HISTOPATHOLOGY FOR ASSESSMENT OF LIVER FIBROSIS IN CHRONIC HCV PATIENTS." JOURNAL OF HEPATOLOGY 58 (2013): S185. Abstract
n/a
El-Shamy, Ahmed, Ikuo Shoji, Wafaa El-Akel, Shymaa E. Bilasy, Lin Deng, Maissa El-Raziky, Da-peng Jiang, Gamal Esmat, and Hak Hotta. "NS5A Sequence Heterogeneity of Hepatitis C Virus Genotype 4a Predicts Clinical Outcome of Pegylated-Interferon-Ribavirin Therapy in Egyptian Patients." JOURNAL OF CLINICAL MICROBIOLOGY 50 (2012): 3886-3892. Abstract
n/a
Elalfy, Mohsen S., Gamal Esmat, Randa M. Matter, Hesham Abdel E. Aziz, and Walid A. Massoud. "Liver fibrosis in young Egyptian beta-thalassemia major patients: relation to hepatitis C virus and compliance with chelation." ANNALS OF HEPATOLOGY 12 (2013): 54-61. Abstract
n/a
Eldin, Noha Sharaf, Soheir Ismail, Hala Mansour, Claire Rekacewicz, Moustafa El-Houssinie, Sherif El-Kafrawy, Saeed El Aidi, Mohamed Abdel-Hamid, Gamal Esmat, Stanislas Pol et al. "Symptomatic Acute Hepatitis C in Egypt: Diagnosis, Spontaneous Viral Clearance, and Delayed Treatment with 12 Weeks of Pegylated Interferon Alfa-2a." PLOS ONE 3 (2008). Abstract
n/a
Elhawary, Eman I., Gamal F. Mahmoud, Mai A. El-Daly, Fatma A. Mekky, Gamal G. Esmat, and Mohamed Abdel-Hamid. "Association of HCV with diabetes mellitus: an Egyptian case-control study." VIROLOGY JOURNAL 8 (2011). Abstract
n/a
ElHefnawi, Mahmoud, Mahmoud Abdalla, Safaa Ahmed, Wafaa elakel, Gamal Esmat, Maissa El Raziky, Shaima Khamis, and Marwa Hassan. "Accurate prediction of response to Interferon-based therapy in Egyptian patients with Chronic Hepatitis C using machine-learning approaches." In 2012 IEEE/ACM INTERNATIONAL CONFERENCE ON ADVANCES IN SOCIAL NETWORKS ANALYSIS AND MINING (ASONAM), 771-778., 2012. Abstract
n/a
Elhelw, Dalia Sherif, Radwa Yehia Mekky, Nada El-Ekiaby, Rasha Ahmed, Mohammad Ahmed Mohey Eldin, Mohammad El-Sayed, Mahmoud Mohammad Abouelkhair, Ayman Salah, Abdel Rahman Zekri, Gamal Esmat et al. "Predictive prognostic role of miR-181a with discrepancy in the liver and serum of genotype 4 hepatitis C virus patients." Biomedical reports 2, no. 6 (2014): 843-848. Abstract

microRNA (miRNA) expression in organs does not always represent their quantity in serum. A disparity in the expression of miR-181a has been reported in the tissues and serum of hepatocellular carcinoma (HCC) patients. Since hepatitis C virus (HCV) is a major cause of HCC and miR-181a has never been studied in HCV, the present study aimed to investigate the miR-181a expression profile in genotype 4 (GT4)-HCV patients to evaluate whether this pattern is also apparent in HCV. RNA was extracted from liver tissues, peripheral mononuclear cells (PBMCs) and serum samples from GT4-HCV-infected patients and healthy donors to evaluate the relative miR-181a expression using quantitative reverse transcription-polymerase chain reaction. miR-181a was significantly higher in the serum of naïve patients compared to controls, and an inverse correlation with the viral load and liver enzymes was apparent. By contrast, no difference in miR-181a expression was observed in the liver tissues and PBMCs of patients compared to controls. This expression observed in HCV is conflicting to that previously reported in HCC. The study also demonstrates a significant upregulation of miR-181a post-interferon/ribavirin treatment in the serum of sustained virological responders (SVRs) compared to non-responders and treatment-naïve SVRs. In conclusion, miR-181a may be considered to be a possible prognostic marker in GT4-HCV infection.

Elhendawy, Mohammed, Lobna Abo-Ali, Sherief Abd-Elsalam, Maha M. Hagras, Ibrahim Kabbash, Loai Mansour, Sherief Atia, Gamal Esmat, Abdel-Raouf Abo-ElAzm, Ferial El-Kalla et al. "HCV and HEV: two players in an Egyptian village, a study of prevalence, incidence, and co-infection." Environmental science and pollution research international 27, no. 27 (2020): 33659-33667. Abstract

The highest recorded hepatitis C virus (HCV) prevalence worldwide is in Egypt. A high prevalence of hepatitis E virus (HEV) in chronic liver disease has been reported. The aim of this study was to study prevalence, incidence, and outcome of HCV infection in an Egyptian Nile Delta village and the relation between HEV infection and HCV-related chronic hepatic affection. This prospective cohort study included 2085 Nagreej village residents. Mass HCV screening was conducted and testing for HEV antibodies among HCV-infected patients performed. The annual incidence of HCV was recorded. Five hundred five (24.22%) of the tested villagers were positive for HCV RNA. Prevalence escalated with age and male sex. The main recorded risk factors were a history of surgery, dental procedures, hospitalization, blood transfusion, and antischistosomal treatment. HEV IgG antibody was positive in 71.4% of individuals with chronic HCV and 96.1% with advanced liver disease (cirrhosis ± hepatocellular carcinoma (HCC)). After 1 year, 29 of the 1390 HCV Ab negative villagers had a positive HCV PCR, placing an annual incidence of new HCV infections at 2.09%. The Egyptian HCV prevalence remains high with infection particularly among the elderly. The annual incidence in a small Nile Delta village is 2.086%. HCV-HEV co-infection may lead to a worse prognosis among Egyptians with chronic liver disease.

Elmakhzangy, HI, C. Rekacewicz, S. Shouman, HN Mohamed, G. Esmat, AA Mansour, A. Ismail, R. Rafaat, M. El Hosseiny, M. El Daly et al. "Early predictors of sustained viral response (SVR) in chronic hepatitis C (Genotype 4) patients treated with pegylated interferon alpha-2a and ribavirin." GASTROENTEROLOGY 128 (2005): A714. Abstract
n/a
Elmakhzangy, HI, G. Esmat, M. Alraziky, ESA Aoun, and M. K. Mohamed. "Hepatocellular carcinoma: The magnitude of the problem in Egypt." GASTROENTEROLOGY 126 (2004): A718. Abstract
n/a
Elsharkawy, A., G. Esmat, M. El Raziky, W. Elakel, M. Abdel-Rahman, and M. Elsayed. "HCV/SCHISTOSOMIASIS COINFECTION: IMPACT ON FIBROSIS AND RESPONSE TO PEGYLATED INTERFERON AND RIBAVIRIN THERAPY." JOURNAL OF HEPATOLOGY 56 (2012): S61. Abstract
n/a
Esmat, G., K. Zalata, M. A. Metwally, H. Khattab, M. El Batanouni, M. El Daly, M. Anwar, A. Hassan, S. Ismail, M. Said et al. "Histopathological characterization of genotype 4 chronic hepatitis C." JOURNAL OF CLINICAL VIROLOGY 36 (2006): S106-S107. Abstract
n/a
Esmat, Gamal, Mohamed Hashem, Mona El-Raziky, Wafaa El-Akel, Suzan El-Naghy, Nehal El-Koofy, Rokaya El-Sayed, Rasha Ahmed, Mohamed Atta-Allah, Mohamed Abdel Hamid et al. "Risk factors for hepatitis C virus acquisition and predictors of persistence among Egyptian children." LIVER INTERNATIONAL 32 (2012): 449-456. Abstract
n/a
Esmat, Gamal, Maissa El Raziky, Aisha Elsharkawy, Dina Sabry, Mohamed Hassany, Amal Ahmed, Noha Assem, Mohamad El Kassas, and Wahid Doss. "Impact of Vitamin D Supplementation on Sustained Virological Response in Chronic Hepatitis C Genotype 4 Patients Treated by Pegylated Interferon/Ribavirin." Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research (2014). Abstract

The current standard of care therapy (SOC) for chronic HCV is pegylated interferon/ribavirin (Peg-IFN/RBV). Many reports showed the possible role of vitamin D supplementation in augmenting the response to SOC. The aim of this study was to assess the role of vitamin D supplementation on the response to treatment in chronic HCV genotype 4 patients. One hundred and one chronic HCV patients were classified into two groups (Group 1): 51 patients received the SOC therapy consisting of Peg-interferon alfa-2b plus ribavirin, (Group 2): 50 patients received the SOC therapy+vitamin D3 (Cholecalciferol) in a dose of 15,000 IU/week during the treatment course. Vitamin D deficiency was found in 95% of patients. No correlation was found between vitamin D levels and stage of fibrosis in the whole population. Vitamin D supplementation had no positive impact on treatment outcome where sustained virological response (SVR) was achieved in 51.2% in group 2 and 71.4% in group 1 by per-protocol analysis and in 44% in group 2 and in 68.6% in group 1 by intention to treat analysis (P value 0.22 and 0.220 respectively). Despite its role in other genotypes, vitamin D supplementation has no significant impact on SVR in HCV Genotype 4 patient. No correlation was found between vitamin D levels and stage of liver fibrosis.

Esmat, G., H. El Makhzangy, S. Males, R. Gad, C. Rekacewicz, S. Ismail, M. Abdel-Hamid, M. El Daly, A. Fontanet, and M. K. Mohamed. "Prediction of treatment outcome in genotype 4 chronic hepatitis C patients during combined interferon and ribavirin therapy." LIVER INTERNATIONAL 26 (2006): 19. Abstract
n/a
Esmat, Gamal. "Hepatitis C in the Eastern Mediterranean Region." EASTERN MEDITERRANEAN HEALTH JOURNAL 19 (2013): 587-588. Abstract
n/a
Esmat, G., A. M. Abouzied, F. Abdel-Aziz, M. K. Mohamed, M. Abdel-Hamid, MS El Raziky, S. A. Ismail, KR Zalata, NN Mikhail, A. Fix et al. "Treatment with Peg-Interferon alfa-2b (PEG-IFN) plus ribavirin compared to interferon alfa-2b (INF alfa-2b)plus ribavirin on subjects with chronic hepatitis C infected with HCV genotype 4." HEPATOLOGY 36 (2002): 364A. Abstract
n/a
Esmat, GH, A. Abouzied, M. Abdel-Hamid, M. K. Mohamed, K. Zalata, MS El Raziky, SA Ismael, M. Said, A. Hasan, M. Anwar et al. "Results of a randomized clinical trial of genotype-4 infected subjects when treated with standard or pegylated interferon alfa-2b in combination with ribavirin." HEPATOLOGY 38 (2003): 314A-315A. Abstract
n/a
Tourism